Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telbivudine to prevent mother-to-infant transmission of HBV in early and mid pregnancy
ChiCTR-OPC-16007899Phase 4Completed
- Sponsor
- Qingdao Chengyang District People's Hospital
- Start
- Jan 2013
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of telbivudine in Chronic Hepatitis B (CHB) (3 arms), sponsored by Qingdao Chengyang District People's Hospital. Primary endpoints: serum levels of HBV DNA, ALT level and 5 more. Started Jan 2013; status: completed.
02
Drugs
telbivudine
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on ChiCTR-OPC-16007899.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-OPC-16007899.